The pause in trials of Britain’s Oxford/AstraZeneca Covid-19 vaccine after an adverse reaction in a participant shows how risky the technology is, and why the developers of Russia’s Sputnik V have chosen another platform.
That’s according to Kirill Dmitriev, CEO of the Russian Direct Investment Fund, which is bankrolling the Russian formula’s development. He was speaking as it was revealed that the British trials were resumed on Saturday with the approval of national regulators.
Continue reading https://on.rt.com/aq8n